These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 38643482)

  • 101. Acetylation of Steroidogenic Acute Regulatory Protein Sensitizes 17β-Estradiol Regulation in Hormone-Sensitive Breast Cancer Cells.
    Manna PR; Molehin D; Ahmed AU; Yang S; Reddy PH
    Int J Mol Sci; 2024 Aug; 25(16):. PubMed ID: 39201419
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Estrogen Receptor Alpha Mutations, Truncations, Heterodimers, and Therapies.
    Hancock GR; Gertz J; Jeselsohn R; Fanning SW
    Endocrinology; 2024 Apr; 165(6):. PubMed ID: 38643482
    [TBL] [Abstract][Full Text] [Related]  

  • 103. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
    Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
    Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
    [TBL] [Abstract][Full Text] [Related]  

  • 104. The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1).
    Najim O; Huizing M; Papadimitriou K; Trinh XB; Pauwels P; Goethals S; Zwaenepoel K; Peterson K; Weyler J; Altintas S; van Dam P; Tjalma W
    Cancer Treat Res Commun; 2019; 19():100123. PubMed ID: 30826563
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Stereospecific lasofoxifene derivatives reveal the interplay between estrogen receptor alpha stability and antagonistic activity in
    Hosfield DJ; Weber S; Li NS; Sauvage M; Joiner CF; Hancock GR; Sullivan EA; Ndukwe E; Han R; Cush S; Lainé M; Mader SC; Greene GL; Fanning SW
    Elife; 2022 May; 11():. PubMed ID: 35575456
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Estrogen Receptor Alpha and ESR1 Mutations in Breast Cancer.
    Patel JM; Jeselsohn RM
    Adv Exp Med Biol; 2022; 1390():171-194. PubMed ID: 36107319
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Cancer statistics, 2024.
    Siegel RL; Giaquinto AN; Jemal A
    CA Cancer J Clin; 2024; 74(1):12-49. PubMed ID: 38230766
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes.
    Rastogi P; O'Shaughnessy J; Martin M; Boyle F; Cortes J; Rugo HS; Goetz MP; Hamilton EP; Huang CS; Senkus E; Tryakin A; Cicin I; Testa L; Neven P; Huober J; Shao Z; Wei R; André V; Munoz M; San Antonio B; Shahir A; Harbeck N; Johnston S
    J Clin Oncol; 2024 Mar; 42(9):987-993. PubMed ID: 38194616
    [No Abstract]   [Full Text] [Related]  

  • 109. ERα/PR crosstalk is altered in the context of the ERα Y537S mutation and contributes to endocrine therapy-resistant tumor proliferation.
    Huggins RJ; Greene GL
    NPJ Breast Cancer; 2023 Nov; 9(1):96. PubMed ID: 38036546
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Young Women with Breast Cancer: The Current Role of Precision Oncology.
    Srikanthan A; Awan AA; McGee S; Rushton M
    J Pers Med; 2023 Nov; 13(11):. PubMed ID: 38003935
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Luminal breast cancer identity is determined by loss of glucocorticoid receptor activity.
    Prekovic S; Chalkiadakis T; Roest M; Roden D; Lutz C; Schuurman K; Opdam M; Hoekman L; Abbott N; Tesselaar T; Wajahat M; Dwyer AR; Mayayo-Peralta I; Gomez G; Altelaar M; Beijersbergen R; Győrffy B; Young L; Linn S; Jonkers J; Tilley W; Hickey T; Vareslija D; Swarbrick A; Zwart W
    EMBO Mol Med; 2023 Dec; 15(12):e17737. PubMed ID: 37902007
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Somatic estrogen receptor α mutations that induce dimerization promote receptor activity and breast cancer proliferation.
    Irani S; Tan W; Li Q; Toy W; Jones C; Gadiya M; Marra A; Katzenellenbogen JA; Carlson KE; Katzenellenbogen BS; Karimi M; Segu Rajappachetty R; Del Priore IS; Reis-Filho JS; Shen Y; Chandarlapaty S
    J Clin Invest; 2024 Jan; 134(1):. PubMed ID: 37883178
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Extended Adjuvant Endocrine Therapy in Early Breast Cancer Patients-Review and Perspectives.
    Bekes I; Huober J
    Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627218
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Sequencing of Endocrine and Targeted Therapies in Hormone-Sensitive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer.
    Jackson EB; Chia SKL
    J Clin Oncol; 2023 Aug; 41(24):3976-3983. PubMed ID: 37406271
    [No Abstract]   [Full Text] [Related]  

  • 115. Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha-Mutant Endometrial Cancer.
    Blanchard Z; Rush CM; Arnesen S; Vahrenkamp JM; Rodriguez AC; Jarboe EA; Brown C; Chang MEK; Flory MR; Mohammed H; Modzelewska K; Lum DH; Gertz J
    Mol Cancer Res; 2023 Oct; 21(10):1023-1036. PubMed ID: 37363949
    [TBL] [Abstract][Full Text] [Related]  

  • 116.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 117.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 118.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 119.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 120.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.